GlassScriptPhysician profile
Judith Zink
NPI 1881760841
$4,519.00
in general payments reported to CMS, 2019-2025
27 companies · $581 in 2025
The $581 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,260 · 2022: $634 · 2023: $1,331 · 2024: $714 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,099.51 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $726.25 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $393.52 | 2021-2023 | |
| Pfizer INC. | $240.73 | 2022-2025 | |
| Biomerieux INC | $185.00 | 2025 | Filmarray |
| Amgen INC. | $163.39 | 2021-2022 | |
| Daiichi Sankyo INC. | $156.23 | 2021-2022 | |
| Glaxosmithkline, LLC. | $137.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.26 | 2023 | |
| Esperion Therapeutics, INC. | $137.00 | 2021 | |
| Alkermes, INC. | $115.95 | 2023 | Vivitrol |
| Lilly USA, LLC | $114.98 | 2022-2023 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $114.91 | 2025 | Voquezna |
| Neurocrine Biosciences, INC. | $113.32 | 2023 | |
| Eisai INC. | $112.24 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $99.65 | 2025 | |
| Dexcom, INC. | $99.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $98.89 | 2023-2025 | Spravato |
| Novo Nordisk INC | $73.76 | 2021-2023 | Rybelsus, Tresiba, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $51.50 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.18 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.04 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.98 | 2021 | |
| Merck Sharp & Dohme LLC | $14.27 | 2021 | |
| Amarin Pharma, INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Zink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.